期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

丙型肝炎治疗及疗效判断指标进展 被引量：6

原文传递
导出
摘要 自1992年美国食品药品监督管理局批准普通干扰素用于治疗丙型肝炎以来，丙型肝炎的抗病毒治疗取得了很大进展。为进一步提高疗效，国内外学者积极探讨基于各种基线因素和早期治疗应答的疗效预测和个体化治疗方案，并加紧研发新型抗HCV药物。
作者 吴晓宁 彭真 贾继东
机构地区 首都医科大学附属北京友谊医院肝病中心
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2010年第11期1100-1103,共4页 Chinese Journal of Laboratory Medicine
关键词 疗效判断指标 抗病毒治疗 丙型肝炎 美国食品药品监督管理局 个体化治疗方案 抗HCV药物 普通干扰素 疗效预测
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献24

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量：732
  • 2Ghany MG,Strader DB,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C:an update.Hepatology,2009,49:1335-1374.
  • 3Toyoda H,Kumada T.Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial:‘2b or not 2b (= 2a),that is the question'.Expert Opin Pharmacother,2009,10:2845-2857.
  • 4Thomas DL,Thio CL,Martin MP,et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.Nature,2009,461:798-801.
  • 5Ge D,Fellay J,Thompson AJ,et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature,2009,461:399-401.
  • 6Tanaka Y,Nishida N,Sugiyama M,et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Nat Genet,2009,41:1105-1109.
  • 7Ferenci P,Fried MW,Shiffman ML,et al.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/tibavirin.J Hepatol,2005,43:425 -433.
  • 8Moreno C,Deltenre P,Pawlotsky JM,et al.Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response:a meta-analysis.J Hepato1,2010,52:25-31.
  • 9Mangia A,Santoro R,Minerva N,et al.Pegintefferon alfa-2b and ribavirin for 12 vs.24 weeks in HCV genotype 2 or3.N Engl J Med,2005,352:2609-2617.
  • 10Davis GL,Wong JB,McHutchison JG,et al.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Hepatology,2003,38:645-652.

二级参考文献15

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献731

同被引文献56

  • 1张为民,李蕴铷,谢雯.丙型肝炎防治指南解读(上)[J].中国临床医生杂志,2006,34(4):23-25. 被引量：14
  • 2贾红宇,盛吉芳,周林福,黄茵,陈智.血清IL-18与IL-10在慢性丙型肝炎发病中作用的临床研究[J].中国感染控制杂志,2006,5(4):303-305. 被引量：6
  • 3董漪,张鸿飞,陈昊,李靖,杨晓晋,朱世殊,程云.小儿慢性丙型肝炎外周血T细胞亚群和TH1／TH2型细胞因子的研究[J].中华实验和临床病毒学杂志,2007,21(1):26-28. 被引量：6
  • 4焦健,王江滨.丙型肝炎抗病毒治疗中的常见问题[J].临床肝胆病杂志,2007,23(4):304-306. 被引量：5
  • 5Kim H J, Park J H, Park D I, et al. Clearance of HCV by Combination Therapy of Pegylated Interferon atpha-2a and Ribavirin Improves Insulin Resistance [J].Gut Liver, 2009 ,3 (2) : 108-115.
  • 6Munoz-Plaza C E, Strauss S, Astone-Twerell J, et al. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S [J]. Int J Drug Policy, 2008, 19(1):71-78.
  • 7Zeuzem S. Interferon-based therapy for chronic hepatitiS C: current and future perspectives [J]. Nat Clin Pract Gastroenterol Hepatol, 2008, 5 ( 11 ) : 610-622.
  • 8Sherman K E. Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof [J]. Ann N Y Acad Sci,2010, 1194: 136-140.
  • 9Bergasa N V, Boyella V D. Liver derived endogenous opioids may interfere with the therapeutic effect of interferon in chronic hepatitis C [ J ]. Med Hypotheses, 2008,70(3) : 556-559.
  • 10Swain MG, Lai MY, Shiffman ML, et al. Durable sustained virological response treatment with peginterferon-2a (pegasys) alone or in combination with ribavirin (copegus) : 5-year follow-up and the criteria of a cure. J Hepatology,2006,46 ( Suppl 1 ) : $3.

引证文献6

二级引证文献19

中华检验医学杂志
2010年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部